Restricted accessResearch articleFirst published online 2026-5
Association of Triglyceride-glucose Index and Obesity Metrics with Cardiovascular Disease Among U.S. Adults with Hyperlipidemia: Findings from the NHANES 2007–2016
Hyperlipidemia constitutes a systemic metabolic disorder. The correlation of cardiovascular disease [CVD] with the triglyceride-glucose index [TyG] in individuals with hyperlipidemia remains unclear. The current study examined the associations of CVD risk with TyG and obesity metrics in individuals with hyperlipidemia in the United States.
Methods:
The present study used a cross-sectional approach utilizing data from the National Health and Nutrition Examination Survey spanning the years 2007–2016. Restricted cubic spline [RCS] and weighted logistic regression [WLR] analyses were executed to evaluate the associations of CVD risk with TyG and obesity metrics in individuals with hyperlipidemia. Subgroup analyses were further performed to evaluate the robustness of these correlations.
Results:
The present study cohort comprised 7144 participants, including 720 with CVD. WLR revealed that TyG-body mass index [BMI], TyG-WC-to-height ratio [WHtR], and TyG-waist circumference [WC] were markedly linked to elevated CVD risk [TyG-BMI: odds ratio (95% confidence interval) = 1.70 (1.21–2.39), P = 0.003; TyG-WC: 1.62 (1.17–2.24), P = 0.004; TyG-WHtR: 1.67 (1.21–2.30), P = 0.002], whereas TyG alone showed no statistically significant correlation [1.14 (0.81–1.61), P = 0.443]. RCS analysis demonstrated a marked linear positive correlation of CVD risk with TyG combined with obesity metrics. Subgroup analyses further verified the robustness and reliability of these findings.
Conclusions:
Among U.S. individuals with hyperlipidemia, no independent association of CVD risk with TyG alone was observed. Nevertheless, TyG combined with obesity metrics exhibited a significant correlation with CVD. TyG integrated with obesity indicators may provide enhanced predictive capability for detecting individuals with heightened early-stage CVD risk among populations with hyperlipidemia.
In ChinaT, HuSS. Report on cardiovascular health and diseases in China 2021: An updated summary. J Geriatr Cardiol, 2023; 20(6):399–430; doi: 10.26599/1671-5411.2023.06.001
FahedG, AounL, Bou ZerdanM, et al.Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci, 2022; 23(2):786; doi: 10.3390/ijms23020786
5.
NayakSS, KuriyakoseD, PolisettyLD, et al.Diagnostic and prognostic value of triglyceride glucose index: A comprehensive evaluation of meta-analysis. Cardiovasc Diabetol, 2024; 23(1):310; doi: 10.1186/s12933-024-02392-y
6.
CheB, ZhongC, ZhangR, et al.Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: An analysis of UK biobank data. Cardiovasc Diabetol, 2023; 22(1):34; doi: 10.1186/s12933-023-01762-2
7.
WardZJ, BleichSN, CradockAL, et al.Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med, 2019; 381(25):2440–2450; doi: 10.1056/NEJMsa1909301
8.
ZhengD, CaiJ, XuS, et al.The association of triglyceride-glucose index and combined obesity indicators with chest pain and risk of cardiovascular disease in American population with pre-diabetes or diabetes. Front Endocrinol (Lausanne), 2024; 15:1471535; doi: 10.3389/fendo.2024.1471535
9.
BayatianA, JangiA, PargarF, et al.Investigating the efficiency of novel indicators in predicting risk of metabolic syndrome in the Iranian adult population. J Educ Health Promot, 2024; 13:385; doi: 10.4103/jehp.jehp_1137_23
10.
LimJ, KimJ, KooSH, et al.Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: An analysis of the 2007-2010 Korean National Health and Nutrition Examination Survey. PLoS One, 2019; 14(3):e0212963; doi: 10.1371/journal.pone.0212963
11.
da SilvaA, CaldasAPS, HermsdorffHHM, et al.Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care. Cardiovasc Diabetol, 2019; 18(1):89; doi: 10.1186/s12933-019-0893-2
12.
GuZ, ZhuP, WangQ, et al.Obesity and lipid-related parameters for predicting metabolic syndrome in Chinese elderly population. Lipids Health Dis, 2018; 17(1):289; doi: 10.1186/s12944-018-0927-x
13.
HuangX, HeJ, WuG, et al.TyG-BMI and hypertension in Normoglycemia subjects in Japan: A cross-sectional study. Diab Vasc Dis Res, 2023; 20(3):14791641231173617; doi: 10.1177/14791641231173617
14.
SongS, SonDH, BaikSJ, et al.Triglyceride Glucose-Waist Circumference (TyG-WC) is a reliable marker to predict non-alcoholic fatty liver disease. Biomedicines, 2022; 10(9):2251; doi: 10.3390/biomedicines10092251
15.
KhamsehME, MalekM, AbbasiR, et al.Triglyceride glucose index and related parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metab Syndr Relat Disord, 2021; 19(3):167–173; doi: 10.1089/met.2020.0109
16.
ZhangS, DuT, ZhangJ, et al.The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis, 2017; 16(1):15; doi: 10.1186/s12944-017-0409-6
17.
XueY, XuJ, LiM, et al.Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. Front Endocrinol (Lausanne), 2022; 13:951689; doi: 10.3389/fendo.2022.951689
18.
MalekM, KhamsehME, ChehrehgoshaH, et al.Triglyceride glucose-waist to height ratio: A novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. Endocrine, 2021; 74(3):538–545; doi: 10.1007/s12020-021-02815-w
19.
ZhangQ, XiaoS, JiaoX, et al.The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: Evidence from NHANES 2001-2018. Cardiovasc Diabetol, 2023; 22(1):279; doi: 10.1186/s12933-023-02030-z
20.
ZhuangY, QiuL, HanD, et al.The association between triglyceride-glucose index and related parameters and risk of cardiovascular disease in American adults under different glucose metabolic states. Diabetol Metab Syndr, 2024; 16(1):102; doi: 10.1186/s13098-024-01340-w
21.
ZhuX, XuW, SongT, et al.Changes in the combination of the triglyceride-glucose index and obesity indicators estimate the risk of cardiovascular disease. Cardiovasc Diabetol, 2024; 23(1):192; doi: 10.1186/s12933-024-02281-4
22.
TuJ, WuB, ChenH, et al.Triglyceride glucose-weight-adjusted waist index (TyG-WWI): The best predictor of diabetes mellitus and mortality risks among TyG and TyG-derived indices. BMC Endocr Disord, 2025; 25(1):166; doi: 10.1186/s12902-025-01989-y
23.
DangK, WangX, HuJ, et al.The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018. Cardiovasc Diabetol, 2024; 23(1):8; doi: 10.1186/s12933-023-02115-9
24.
TamargoIA, BaekKI, XuC, et al.HEG1 protects against atherosclerosis by regulating stable flow-induced KLF2/4 expression in endothelial cells. Circulation, 2024; 149(15):1183–1201; doi: 10.1161/circulationaha.123.064735
25.
TakaokaM, ZhaoX, LimHY, et al.Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis. Nature, 2024; 634(8033):457–465; doi: 10.1038/s41586-024-07993-x
26.
SimhaV. Management of hypertriglyceridemia. Bmj, 2020; 371:m3109; doi: 10.1136/bmj.m3109
27.
DolzhenkoMM, BarnettOY, GrassosC, et al.Management of dyslipidemia in individuals with low-to-moderate cardiovascular risk: Role of nutraceuticals. Adv Ther, 2020; 37(11):4549–4567; doi: 10.1007/s12325-020-01490-z
28.
KarrS. Epidemiology and management of hyperlipidemia. Am J Manag Care, 2017; 23(9 Suppl):S139–S148.
29.
WangL, CongHL, ZhangJX, et al.Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol, 2020; 19(1):80; doi: 10.1186/s12933-020-01054-z
30.
WangY, ChengT, ZhangT, et al.Association of triglyceride glucose index with incident diabetes among individuals with normal fasting triglycerides and fasting plasma glucose values: A general population-based retrospective cohort study. Front Endocrinol (Lausanne), 2025; 16:1598171; doi: 10.3389/fendo.2025.1598171
31.
WangJ, SunX, JiaoL, et al.Clinical characteristics and variant analyses of transient infantile hypertriglyceridemia related to GPD1 gene. Front Genet, 2022; 13:916672; doi: 10.3389/fgene.2022.916672
32.
WilsonSM, MaesAP, YeomanCJ, et al.Determinants of the postprandial triglyceride response to a high-fat meal in healthy overweight and obese adults. Lipids Health Dis, 2021; 20(1):107; doi: 10.1186/s12944-021-01543-4
33.
GaubatzJW, GillardBK, RosalesC, et al.Dietary alcohol and fat differentially affect plasma cholesteryl ester transfer activity and triglycerides in normo- and hypertriglyceridemic subjects. Lipids, 2020; 55(4):299–307; doi: 10.1002/lipd.12237
34.
SettasN, PerskyR, FauczFR, et al.SGPL1 deficiency: A rare cause of primary adrenal insufficiency. J Clin Endocrinol Metab, 2019; 104(5):1484–1490; doi: 10.1210/jc.2018-02238
35.
TemmokuJ, AsanoT, SaitoK, et al.Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Mod Rheumatol Case Rep, 2022; 6(1):41–46; doi: 10.1093/mrcr/rxab020
36.
BrandonR, JiangY, YeuRQ, et al.Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial. Front Endocrinol (Lausanne), 2022; 13:1091421; doi: 10.3389/fendo.2022.1091421
37.
HosseiniH, BagherniyaM, SahebkarA, et al.The effect of curcumin-piperine supplementation on lipid profile, glycemic index, inflammation, and blood pressure in patients with type 2 diabetes mellitus and hypertriglyceridemia. Phytother Res, 2024; 38(11):5150–5161; doi: 10.1002/ptr.8304
38.
ZhangH, DhallaNS. The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. Int J Mol Sci, 2024; 25(2):1082; doi: 10.3390/ijms25021082
39.
ShaitoA, AramouniK, AssafR, et al.Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. Front Biosci (Landmark Ed), 2022; 27(3):105; doi: 10.31083/j.fbl2703105
40.
PourfarzamM, ZadhoushF, SadeghiM. The difference in correlation between insulin resistance index and chronic inflammation in type 2 diabetes with and without metabolic syndrome. Adv Biomed Res, 2016; 5:153; doi: 10.4103/2277-9175.188489
41.
QiL, GroegerM, SharmaA, et al.Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system. Nat Commun, 2024; 15(1):7991; doi: 10.1038/s41467-024-52258-w
42.
YanaiH, AdachiH, HakoshimaM, et al.Postprandial hyperlipidemia: Its pathophysiology, diagnosis, atherogenesis, and treatments. Int J Mol Sci, 2023; 24(18):13942; doi: 10.3390/ijms241813942
43.
GillPK, DronJS, BerberichAJ, et al.Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia. J Clin Lipidol, 2021; 15(1):79–87; doi: 10.1016/j.jacl.2020.11.006
44.
LiuY, XiangH, XiongW, et al.Glucolipotoxicity induces endothelial cell dysfunction by activating autophagy and inhibiting autophagic flow. Diab Vasc Dis Res, 2022; 19(3):14791641221102513; doi: 10.1177/14791641221102513
45.
MadonnaR, De CaterinaR. Cellular and molecular mechanisms of vascular injury in diabetes—Part I: Pathways of vascular disease in diabetes. Vascul Pharmacol, 2011; 54(3–6):68–74; doi: 10.1016/j.vph.2011.03.005
46.
KimH, LeeH. Risk of stroke and cardiovascular disease according to diabetes mellitus status. West J Nurs Res, 2023; 45(6):520–527; doi: 10.1177/01939459231158212
47.
HouXZ, LvYF, LiYS, et al.Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study. Cardiovasc Diabetol, 2024; 23(1):86; doi: 10.1186/s12933-024-02173-7
48.
TahaparyDL, PratisthitaLB, FitriNA, et al.Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr, 2022; 16(8):102581; doi: 10.1016/j.dsx.2022.102581
49.
TianZ, YangL, LiY, et al.Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: A prospective cohort study from UK biobank. Cardiovasc Diabetol, 2025; 24(1):257; doi: 10.1186/s12933-025-02819-0
